Status:

UNKNOWN

Critical Periods After Stroke Study (CPASS)

Lead Sponsor:

MedStar National Rehabilitation Network

Collaborating Sponsors:

Georgetown University

University of Wisconsin, Madison

Conditions:

Stroke

Brain Infarction

Eligibility:

All Genders

21+ years

Phase:

NA

Brief Summary

To perform an exploratory single center randomized study that will form the basis for a larger scale, more definitive randomized clinical trial to determine the optimal time after stroke for intensive...

Detailed Description

Please see the following reference: Dromerick, A.W., Edwardson, M., Edwards, D.F., Giannetti, M.L., Barth, J., Brady, K.P., Chan, E., Tan, M.T., Tamboli, I., Chia, R., Orquiza, M., Padilla, R.M., Che...

Eligibility Criteria

Inclusion

  • Ischemic or hemorrhagic stroke (with confirmatory neuroimaging) within 28 days of admission to inpatient rehabilitation (allows those randomized to the early arm to begin study-related treatment within 30 days)
  • Age \>21 years
  • Able to participate in first study-related treatment session within 30 days of stroke onset
  • Able to participate in all study-related activities, including one year follow up and blood draws
  • Persistent hemiparesis leading to impaired upper extremity function. Hemiparesis as indicated by NIHSS Motor Arm score ≥ 1
  • Recovering moderate motor impairment at the shoulder and elbow or hand such as:
  • Proximal UE voluntary activity indicated by a score of ≥ 3 on the upper arm item of the Motor Assessment Scale - wrist and finger movement is not required
  • or
  • Manual Muscle Test (MMT) score of ≥ 2 on shoulder flexion or abduction and MMT score of ≥ 2 for any of the following: elbow flexion, elbow extension, wrist flexion, wrist extension, finger flexion or finger extension.
  • or
  • Active range of motion (AROM) to at least 50% of range in gravity eliminated position for shoulder flexion or abduction, and for any of the following motions: elbow flexion, elbow extension, wrist flexion, wrist extension, finger flexion or finger extension.
  • Score of ≤ 8 on the Short Blessed Memory Orientation and Concentration Scale
  • Follows 2 step commands
  • No upper extremity injury or conditions that limited use prior to the stroke
  • Pre-stroke independence: Modified Rankin Score 0 or 1

Exclusion

  • Inability to give informed consent
  • Prior stroke with persistent motor impairment or other disabling neurologic condition such as multiple sclerosis, parkinsonism, amyotrophic lateral sclerosis (ALS), dementia requiring medication
  • Rapidly improving motor function
  • Clinically significant fluctuations in mental status in the 72 hours prior to randomization
  • Hemispatial neglect as determined by \>3 errors on the Mesulam Symbol Cancellation Test
  • Not independent prior to stroke (determined by scores of \<95 on Barthel Index or \>1 on Modified Rankin Scale
  • Dense sensory loss indicated by a score of 2 on NIHSS sensory item
  • Ataxia out of proportion to weakness in the affected arm as described by a score of ≥ 1 on the NIHSS limb ataxia item
  • Active or prior psychosis within 2 years
  • Active or prior (within 2 years) substance abuse
  • Not expected to survive 1 year due to other illnesses (cardiac disease, malignancy, etc)
  • Received upper extremity botulinum toxin within 6 months (other medications do not exclude)

Key Trial Info

Start Date :

August 26 2014

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 31 2021

Estimated Enrollment :

150 Patients enrolled

Trial Details

Trial ID

NCT02235974

Start Date

August 26 2014

End Date

January 31 2021

Last Update

April 7 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

MedStar National Rehabilitation Hospital

Washington D.C., District of Columbia, United States, 20010